Analyst Price Targets — PRQR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 26, 2026 12:51 am | Keay Nakae | Chardan Capital | $3.00 | $1.57 | TheFly | ProQR Therapeutics price target lowered to $3 from $4 at Chardan |
| March 14, 2024 5:02 am | Keay Nakae | Loop Capital Markets | $2.50 | $2.32 | StreetInsider | ProQR Therapeutics N.V. (PRQR) PT Raised to $2.50 at Chardan Capital Markets |
| December 30, 2022 2:09 am | Raymond James Raymond James | Raymond James | $5.00 | $3.37 | Pulse 2.0 | ProQR Therapeutics (PRQR) Stock Gets A $5 Price Target |
| December 22, 2022 9:59 am | Jennifer Kim | Cantor Fitzgerald | $5.00 | $2.70 | StreetInsider | Cantor Fitzgerald Upgrades ProQR Therapeutics N.V. (PRQR) to Overweight |
| August 12, 2022 5:08 am | Keay Nakae | Chardan Capital | $2.00 | $0.82 | TheFly | ProQR Therapeutics downgraded to Neutral from Buy at Chardan |
Latest News for PRQR
ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data. PRQR differentiates itself by prioritizing NTCP modulation in rare pediatric liver disease (biliary atresia), aiming for a faster, cleaner clinical validation path than competitors. Recent financings, including a $50M…
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”)…
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change (6 mg/kg) in total bile acids in serum, exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation, along with concordant readouts of bile acid profile and…
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the…
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRQR.
U.S. House Trading
No House trades found for PRQR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.